A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAZODALIBEP IN PARTICIPANTS WITH SJOGREN'S SYNDROME WITH MODERATE TO SEVERE SYMPTON STATE

Registry ID

HZNP-DAZ-303

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HORIZON THERAPEUTICS IRELAND DAC

Start date

2024-06-20

Last update

2024-03-25

Conditions

• SJOGREN'S SYNDROME

Related clinical trials

• A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER PHASE 3 PROTOCOL TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULTS WITH MODERATE TO SEVERE SJÖGREN'S DISEASE (SJD)
• A RANDOMIZED, DOUBLE-BLIND 2-ARM NEPTUNUS EXTENSION STUDY TO ACCESS THE LONG-TERM SAFETY AND EFFICACY OF IANALUMAB IN PATIENTS WITH SJOGREN'S SYNDROME
• A 48-WEEK, 6-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER TRIAL TO ASSESS THE SAFETY AND EFFICACY OF MULTIPLE CFZ533 DOSES ADMINISTERED SUBCUTANEOUSLY IN TWO DISTINCT POPLUATIONS OF PATIENTS WITH SJOGREN'S SYNDROME (TWINSS)

View on source registry